ePharmacy Market Analysis Size, Growth | Industry Report, 2025

The global ePharmacy market is expected to reach USD 109.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by constant increase in the number of internet users, improved access to web-based & online services, and rapid increase in aging population who find it difficult to visit pharmacies. Convenience, affordability, and ease in availability of medicines are fueling market growth.

Increase in prevalence of chronic conditions and diseases across the globe is resulting in constant growth in demand for various drugs and healthcare products. High cost of treatment is indicating the need to reduce health care cost. Online pharmacies are gaining popularity owing to lucrative offers such as price discounts that result in cost savings. In addition, increase in adoption of e-prescriptions in hospitals and other healthcare facilities is further expected to boost growth.

High unmet needs of emerging economies is one of the key driving factors. Government initiatives, increase in investments, changing regulations, and increasing penetration of internet and broadband in urban as well as rural areas are contributing to the growth of the market. Many new players are entering the market as the healthcare sector is offering huge potential to the online health retailers due to the ever growing demand for healthcare products and services.

However, growth in illegal online pharmacies is restraining the growth. These illegitimate websites may offer counterfeit and unapproved drugs, which make people skeptical about purchasing medicines online.

Further Key Findings From the Report Suggest:

• North America held majority of the share in 2016 due to increase in online purchases, growing elderly population, and high adoption of IT in healthcare
• The U.S. is the largest market in North America owing to the presence of various key players and a large tech-savvy population
• Asia Pacific is expected to be the fastest growing segment due to the presence of emerging economies like China & India and improving infrastructure

• Some of the key players are The Kroger Co., Walgreen Co.; Wal-Mart Stores, Inc.; CVS Health; Express Scripts Holding Company; Giant Eagle, Inc.; DocMorris (Zur Rose Group); Rowlands Pharmacy; and OptumRx, Inc.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/epharmacies-market

Operating Room Equipment Market Size, Growth | Industry Report, 2025

The global operating room equipment market is expected to reach USD 48.50 billion by 2025 according to a new report by Grand View Research, Inc. The market is primarily driven by increasing investments for improving hospital care facilities, rising number of new hospitals & ambulatory care centers, increasing patient preference for minimally invasive procedures, and an increase in the number of surgeries performed globally.

Growing funds & investments by various government bodies and private investors are also contributing to the growth of the market. For instance, in its 2016-17 budget, the Hong Kong government dedicated a provision of USD 200 billion for a ten-year hospital development plan that would help expand and upgrade healthcare facilities. Under the plan, number of operating theaters would increase by 40% and specialist outpatient service capacity would increase by 40% from 6.8 million to 10 million attendances for a year. The development plan also includes redevelopment and expansion of various hospitals in the region.

In addition, a rapid increase in the number of elderly people & rising prevalence of chronic diseases are increasing the demand for surgical interventions and contributing to the expansion of the market. Technological innovations in medical devices are driving the adoption of advanced medical equipment in surgical procedures. Key players are focusing on product innovations and new launches to cope with growing needs.

Furthermore, improving healthcare infrastructure in emerging economies, large patient pool, and untapped opportunities in developing nations are attracting foreign investors to hospitals and the healthcare sector. Thus, growing investments in emerging economies and establishment of new hospitals & healthcare centers are expected to boost growth in the next few years.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/operating-room-equipment-market

Further Key Findings From the Report Suggest:

• The anesthesia devices segment held majority of the revenue share in 2016 due to a rise in the volume of surgical procedures
• Hospitals dominated the end-use segment in 2016 primarily due to increasing number of hospitals and rising investments in operating theaters
• North America dominated the global market owing to a rapid increase in geriatric population and rising prevalence of various diseases

• Some of the key players includeSTERIS plc; Stryker; KARL STORZ GmbH & Co. KG; GE Healthcare; Siemens Healthineers; and Hill-Rom (Trumpf Medical)

Grand View Research has segmented the operating room equipment market on the basis of product, end-use, and region:

Operating Room Equipment Product Outlook (Revenue, USD Million, 2014 - 2025)

• Anesthesia Devices
• Endoscopes
• Operating Room Tables
• Operating Room Lights
• Electrosurgical Devices
• Surgical Imaging Devices
• Patient Monitors
• Others

Operating Room Equipment End-Use Outlook (Revenue, USD Million, 2014 - 2025)

• Hospitals
• Ambulatory Surgical Centers

Operating Room Equipment Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
• Asia Pacific
  • China
  • Japan
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa

Aminoglycosides Market Analysis By Drug, Mode of Administration, Application and Forecast to 2022

Global Aminoglycoside Market is expected to reach USD 1.68 billion by 2022 growing at an estimated CAGR of 3.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics. 

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry. 

Further key findings from the report suggest:

• Neomycin and tobramycin together contributed for over USD 600 million as revenue in this market owing to higher usage and prescription of these drugs for treatment of different bacterial infections. Neomycin finds higher usage in topical formulations for treatment of different skin infections.
• Injectables accounted for the largest share of revenue amongst other routes of administration owing to higher usage for treatment of tuberculosis, MDR-TB, and XDR-TB. Use of second line anti tuberculosis drugs such as kanamycin & capreomycin by global organizations is attributive for generation of maximum revenue in this segment.
• Human use for treatment of respiratory disorders accounted for largest share in applications segment owing to rise in global incidence of tuberculosis. Furthermore, other bacterial infections of respiratory tract that can be treated using aminoglycoside class of antibiotics are anticipated to contribute for expected growth in this segment.
• Veterinary treatment is expected to boost industrial growth in the coming years owing to higher incidence of animal diseases outbreaks. However, these drugs have restrictive regulations for administration to food-producing animals as it may lead to toxic effects and resistance development on humans after consumption of animal originated food.
• Asia Pacific was the largest market, accounting for over 40% of revenue in aminoglycoside industry owing to, the presence of market players in this region coupled with higher rate of tuberculosis incidences herein.
• South Africa spearheaded growth in the MEA market. The presence of relatively higher demand and consumption of injectable solutions in this region because of increase in incidence rate of MDR-TB and other drug resistant infections are some regional growth drivers.
• Key participants of the aminoglycoside market include Vega Pharma Ltd., Kremoint Pharma Pvt. Ltd, Xian Wison Biological Technology Co., Ltd., Jiangxi Bolai Pharmacy Co., Ltd., Medson Pharmaceuticals, Hangzhou Uniwise International Co., Ltd., Yi Chang Veterinary Medicine Factory, HuvePharma, and Medico Remedies Pvt. Ltd.
• Market players are involved in the development of products with newer formulations and lesser side effects in order to treat eradicate bacterial infections that are resistant to other class of antibiotics.

Browse Details @ http://www.grandviewresearch.com/industry-analysis/aminoglycoside-market

Complementary and Alternative Medicine Market Size, Share, Growth and Forecast to 2026

The global Complementary And Alternative Medicine Market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues.

Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period.

Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data.

Further key findings from the report suggest:

• The market is driven by high adoption of herbal dietary supplements and other wellness therapies like yoga, and acupuncture
• Botanical has become the most prominent form of alternative medicine as the segment was observed to hold the largest market share in terms of revenue 2018
• Europe and Asia Pacific in combination are anticipated to hold a major market share in terms of revenue over the forecast period
• Developing regions such as Latin America and Middle East Africa are set to witness considerable growth in demand over the forecast period driven by high cost of conventional medicine and lack of their availability in certain countries
• Some of the key players and wellness institutes active in the complementary and alternative medicine market are Columbia Nutritional Inc.; Herb Pharm; Herbal Hills; Helio USA Inc.; Deepure Plus; Nordic Naturals; Pure encapsulations, Inc.; and other wellness institutes like Iyengar Yoga Institute; John Schumacher’s Unity Woods Yoga Center; Yoga Tree; The Healing Company; and Quantum Touch Inc.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/aternative-medicine-therapies-market

Personalized Medicine (PM) Market Insights - Industry Analysis and Forecast to 2022

Global Personalized Medicine Market is expected to reach USD 2,452.5 billion by 2022; according to a new study by Grand View Research, Inc. Growing number of approved companion diagnostics and biomarkers have aided the development of advanced personalized diagnostic tests and enhanced the level of treatment monitoring for a range of complex diseases. A significant number of diagnostics and therapeutic products, which are currently under clinical development and investigational research, are associated with one or the other proteomic or genomic markers and fall under category of companion diagnostics.

Personalized medicine finds extensive and indispensable applications in the field of oncology. Furthermore, a marked technological advancement of next generation sequencing is expected to significantly enhance market usage rates owing to, a considerable decrease in the costs of whole genome sequencing and is expected to improve the demand for personalized medical diagnostic and therapeutic products over the forecast period. Personalized medical care and nutrition accounted for the largest share of the market in 2014 owing to, the presence of a significantly large consumer base, relatively less number of regulatory mandates, and the over-the-counter nature of retail nutrition products. This large share is also due to, the highly capital-intensive nature of implementation of healthcare information technology and telemedicine applications.

Further key findings from the study suggest:

• Personalized nutrition and wellness was the largest product segment of the market in 2014. Growing population considerably high market usage and high accessibility are amongst key factors accounting for its large share. Moreover, the core segments of this market viz., personalized medicine diagnostics and therapeutics are expected to grow at the fastest rate over the forecast period due to, ongoing technological advancements in genetic medicine.
• North America was the largest regional market in 2014, with revenue estimated at over USD 500.0 billion. Presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to cancer research, and the presence of high patient and practitioner awareness levels are some key drivers of this market.
• Asia Pacific is expected to witness lucrative growth of over 13.0% over the forecast period. The presence of a large population base, high market penetration of segments such as complementary and alternative medicine, growing collaborative initiatives between western and eastern market participants are some key factors expected to drive regional market growth over the forecast period.
• Key players of this market include GE Healthcare, Illumina Inc., Quest Diagnostics, Abbott Diagnostics, Affymetrix, and Bayer Healthcare. Large presence of biotechnology and pharmaceutical manufacturers is expected to keep the industry rivalry at high levels throughout the forecast period. Moreover, the presence of extensive R&D to capitalize on novel growth opportunities is expected to further intensify competition over the forecast period.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/personalized-medicine-market

Rosacea Treatment Market Size, Growth and Forecast to 2025 | Grand View Research

The global Rosacea Treatment Market size is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 6.8% over the forecast period. Several factors such as an advanced formulations and high prevalence of the disease are forecasted to fuel the market growth.

Rosacea affects more than 400 million people worldwide and the global incidence among adults is estimated at 5%. Less than 1.5 million patients seek treatment, making it a highly underdiagnosed condition. This disease has a higher incidence in women than men, with several studies claiming a possible association between rosacea and menopause. In the absence of an absolute cure, treatment options are largely focused on management of the disease.

The market for rosacea treatment is majorly genericized due to multiple patent expiries, leading to a highly fragmented therapeutic landscape. Rosacea is an underdiagnosed condition and is frequently misdiagnosed as acne. Off-label use of therapeutics pose an intensely competitive space for rosacea-specific treatments.

Topical therapies remain the mainstay for treatment. Topical products captured more than 60% market share in 2017. Although topical items are expected to maintain their lead over oral medicines through the forecast period, the market is witnessing a paradigm shift supported by the increasing inclination towards combination products.

Therapeutic options available for rosacea treatment are antibiotics, alpha agonists, retinoids, immunosuppressants, corticosteroids, antihypertensive agents, and others. Antibiotics are prescribed for the first-line treatment, making them the dominant drug class in 2017-a trend expected to continue through 2025.

The rosacea treatment market growth is supported by strong commercial sales from key products such as Rhofade, Mirvaso, Oracea, MetroGel, Noritate, and Finacea. Although increased penetration of generic drugs is a constraining factor, the impending launch of several promising pipeline products indicate an optimistic future for the global market.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/rosacea-treatment-market

Breakthrough Therapy (BT) Designation Market Analysis Report and Forecast to 2025

The global Breakthrough Therapy Designation Market is anticipated to reach USD 144.6 billion by 2025, according to a new report by Grand View Research, Inc. Breakthrough Therapy (BT) designation is granted to drugs that display substantial results in the treatment of life-threatening diseases in initial stages of the drug development process. Expedited regulatory process in North America and EU regions is driving growth. Increase in the number of innovative molecules receiving the BT status, coupled with rise in the demand for orphan drugs as well as those for the treatment of cancer, is anticipated to boost the market over the forecast period.

The development time of BT therapy is 30.0% to 50.0% lesser than those without the designation. This significantly increases the net present value of investigational molecule. Reduction in the development time of these drugs is expected to accelerate their approval process as compared to standard drugs as well as boost growth opportunities. The BT tag also increases the value of the drug due to its high scientific value.

There has been a consistent rise in the number of drugs receiving BT status in the U.S., and this trend is also expected to drive the number of applications submitted for the same, thereby contributing to the market growth.

Further Key Findings From the Study Suggest:

• The infectious diseases segment dominated the market in 2016. However, it is expected to exhibit moderate growth in the forecast period owing to decline in sales of blockbuster drugs such as Harvoni and Sovaldi
• Oncology is expected to be the dominating segment over the forecast period owing to rise in the demand for cancer medicines and increase in the number of oncology molecules gaining BT status. As of 2017, the number of molecules gaining BT status is the highest in this segment
• The rare diseases segment is estimated to exhibit fastest growth owing to rise in demand and increase in the R&D pipeline of orphan drugs
• North America is expected to dominate the market over the forecast period owing to well-established intellectual property laws and preference of patients and healthcare professionals for innovative medicines
• Some of the key players are F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Pfizer, Inc.; AbbVie, Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; Eli Lilly and Company; Sanofi; Regeneron; AcadiaPharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Amgen, Inc.; AstraZeneca; and GlaxoSmithKline plc.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/breakthrough-therapy-bt-designation-market